Evaluating DCR-STAT3 for adults with solid tumors

An Open-label, Phase 1, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous DCR-STAT3 in Adults With Refractory Solid Tumors

This study is testing a new treatment called DCR-STAT3 to see if it can help adults with solid tumors that haven’t improved with other therapies.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Novo Nordisk A/S (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy
• Locations: 2 sites (Dallas, Texas and 1 other locations)
• Trial ID: NCT06098651 on ClinicalTrials.gov

What this trial studies

This interventional study aims to assess the safety and tolerability of DCR-STAT3 in adults suffering from refractory solid tumors. It is a first-in-human, ascending-dose, multicenter trial that will also evaluate the potential antitumor effects of STAT3 knockdown through blood biomarkers and imaging techniques. Participants will receive DCR-STAT3 as a monotherapy, and the study will utilize RECIST 1.1 criteria to measure tumor response. The trial is designed for patients who have not responded to standard therapies.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with locally advanced or metastatic solid tumors that have not responded to standard therapies.

Not a fit: Patients with solid tumors that are amenable to surgical intervention or those who have not progressed on standard therapies may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with refractory solid tumors.

How similar studies have performed: While this approach is novel, similar studies targeting STAT3 have shown promise in early-phase trials.

Eligibility criteria

Inclusion Criteria:

* Age
* ≥ 18 years of age inclusive, at the time of signing the informed consent.

Type of Participant and Disease Characteristics

- Documented locally advanced or metastatic solid tumor malignancy or non-Hodgkin's lymphoma that is refractory to standard therapy known to provide clinical benefit for their condition or for which no standard therapy is available

* Demonstrated evidence of disease progression, via imaging, during or following standard therapy known to provide clinical benefit for their condition
* Demonstrated intolerance to standard therapy known to provide clinical benefit for their condition
* Measurable disease according to RECIST version 1.1 (as determined by CT or MRI)
* Malignancy not currently amenable to surgical intervention due to medical contraindication or non-resectability of the tumor
* ECOG performance status of 0, 1, or 2, and an anticipated life expectancy of ≥ 3 months

Weight

- BMI ≥ 18 kg/m2

Sex

Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 24 weeks after the last dose of study intervention:

1. Refrain from donating sperm

   AND, either:
2. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent OR
3. Must agree to use a male condom when having sexual intercourse with a WOCBP who is not currently pregnant

Female participants are eligible to participate if they are not pregnant or breastfeeding, and one of the following conditions applies:

1. Is not a WOCBP OR
2. Is a WOCBP and:

   is using a contraceptive method that is highly effective, with a failure rate of \< 1%, as described in Section 10.4 during the study intervention period and for at least 24 weeks after the last dose of study intervention. The Investigator should evaluate the potential for contraceptive method failure (e.g., noncompliance, recently initiated) in relationship to the first dose of study intervention.

   must have a negative highly sensitive pregnancy test (serum as required by local regulations) on Day 1 of each cycle before the first dose of study intervention

   Exclusion Criteria:

   Prior/Concomitant Therapy

   - Other concurrent (within 28 days of Day 1, Cycle 1) chemotherapy, immunotherapy, or radiotherapy. Note that hormonal therapy (e.g., tamoxifen, LHRH agonists) is allowed.

   - Requirement for palliative radiotherapy to lesions that are defined as target lesions by RECIST version 1.1 criteria at the time of study entry
   * Continued compromise or inadequate recovery from a prior anti-neoplastic therapy
   * Known hypersensitivity to any of the components of DCR-STAT3
   * Long-term immunosuppressive therapy

   Prior/Concurrent Clinical Study Experience
   * Treatment with investigational therapy(ies) within 5 half-lives of the investigational therapy prior to the first scheduled day of dosing with DCR-STAT3, or 4 weeks if the half-life of the investigational agent is not known

   Diagnostic assessments - Seropositive for antibodies to HIV, HBV, or HCV at Screening (historical testing may be used if performed within the 3 months prior to screening). NOTE: In participants with previous treatment for hepatitis C with direct-acting HCV medication and seropositivity for HCV, or in participants with prior infection and spontaneous resolution, HCV RNA must be undetectable (at least 2 negative HCV RNA tests at least 12 weeks apart), and the HCV infection must have been resolved or cured \> 3 years prior to initial dosing with the investigational medication.

Where this trial is running

Dallas, Texas and 1 other locations

• Next Oncology — Dallas, Texas, United States (Recruiting)
• Next Oncology — San Antonio, Texas, United States (Recruiting)

Study contacts

• Study coordinator: Vinita Uttamsingh

Conditions Solid Tumor, Adult; Refractory Tumor